Search Results Search Sort by RelevanceMost Recent State of the Art and Science Aug 2020 American College of Preventive Medicine Statement on Prioritizing Prevention in Opioid Research Hunter Jackson Smith, MD, MPH, MBE, Elizabeth Salisbury-Afshar, MD, MPH, Bob Carr, MD, MPH, and Stephanie Zaza, MD, MPH Opioid use research has focused mainly on treatment and overdose responses. Clinically and ethically, these priorities should change. AMA J Ethics. 2020;22(8):E687-694. doi: 10.1001/amajethics.2020.687. Case and Commentary Aug 2017 Should Clinicians Medicate against Structural Violence? Potential Iatrogenic Risks and the Need for Social Interventions Lauren E. Hock, MD and Niranjan S. Karnik, MD, PhD Risks of off-label medication to treat aggression should be balanced with consequences of not responding to social factors. AMA J Ethics. 2017;19(8):753-761. doi: 10.1001/journalofethics.2017.19.8.ecas2-1708. Case and Commentary Jun 2011 Herbal Supplements as Placebos Valerie Jones, MD Even if a placebo is safe, it should not be employed as a way of mollifying patients or glossing over underlying causes of illness. Virtual Mentor. 2011;13(6):354-358. doi: 10.1001/virtualmentor.2011.13.6.ccas3-1106. Case and Commentary Jan 2009 Outpatient Commitment: A Treatment Tool for the Mentally Ill? Commentary 2 Ann Hackman, MD Benefits and risks of outpatient commitment are a means for managing mental illness in patients who are homeless. Virtual Mentor. 2009;11(1):9-12. doi: 10.1001/virtualmentor.2009.11.1.ccas1-0901. Case and Commentary Jan 2009 Outpatient Commitment: A Treatment Tool for the Mentally Ill? Commentary 1 Scott C. Fears, MD, PhD Benefits and risks of outpatient commitment are a means for managing mental illness in patients who are homeless. Virtual Mentor. 2009;11(1):6-9. doi: 10.1001/virtualmentor.2009.11.1.ccas1-0901.
State of the Art and Science Aug 2020 American College of Preventive Medicine Statement on Prioritizing Prevention in Opioid Research Hunter Jackson Smith, MD, MPH, MBE, Elizabeth Salisbury-Afshar, MD, MPH, Bob Carr, MD, MPH, and Stephanie Zaza, MD, MPH Opioid use research has focused mainly on treatment and overdose responses. Clinically and ethically, these priorities should change. AMA J Ethics. 2020;22(8):E687-694. doi: 10.1001/amajethics.2020.687.
Case and Commentary Aug 2017 Should Clinicians Medicate against Structural Violence? Potential Iatrogenic Risks and the Need for Social Interventions Lauren E. Hock, MD and Niranjan S. Karnik, MD, PhD Risks of off-label medication to treat aggression should be balanced with consequences of not responding to social factors. AMA J Ethics. 2017;19(8):753-761. doi: 10.1001/journalofethics.2017.19.8.ecas2-1708.
Case and Commentary Jun 2011 Herbal Supplements as Placebos Valerie Jones, MD Even if a placebo is safe, it should not be employed as a way of mollifying patients or glossing over underlying causes of illness. Virtual Mentor. 2011;13(6):354-358. doi: 10.1001/virtualmentor.2011.13.6.ccas3-1106.
Case and Commentary Jan 2009 Outpatient Commitment: A Treatment Tool for the Mentally Ill? Commentary 2 Ann Hackman, MD Benefits and risks of outpatient commitment are a means for managing mental illness in patients who are homeless. Virtual Mentor. 2009;11(1):9-12. doi: 10.1001/virtualmentor.2009.11.1.ccas1-0901.
Case and Commentary Jan 2009 Outpatient Commitment: A Treatment Tool for the Mentally Ill? Commentary 1 Scott C. Fears, MD, PhD Benefits and risks of outpatient commitment are a means for managing mental illness in patients who are homeless. Virtual Mentor. 2009;11(1):6-9. doi: 10.1001/virtualmentor.2009.11.1.ccas1-0901.